CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics, Inc. (Nasdaq: SAGE ), a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,157,894 shares of its common stock at a public offering price of $47.50 per share, before underwriting discounts. In addition, SAGE has granted the underwriters a 30-day option to purchase up to an additional 473,684 shares of its common stock.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Partners LLC and Cowen and Company, LLC are serving as lead managers and Canaccord Genuity Inc. is serving as co-manager. The offering is expected to close on January 12, 2016, subject to customary closing conditions.
SAGE anticipates the total gross proceeds from the offering (before deducting underwriters' discounts and commissions and estimated offering expenses) will be approximately $150.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
The shares are being offered by SAGE pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on January 5, 2016. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov .
When available, copies of the final prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting one of the following: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 866-803-9204; or Goldman, Sachs, & Co., Attn: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: prospectus-ny@ny.email.gs.com .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Sage Therapeutics Sage Therapeutics (NASDAQ: SAGE ) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders.
Forward-Looking Statements Various statements in this release concerning SAGE's future expectations, plans and prospects, including without limitation, SAGE's expectations regarding the closing of its public offering, and the development and possible future launch of its product candidates constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond SAGE’s control, which could cause actual results to differ materially from those indicated by these forward-looking statements, including, without limitation: uncertainties related to market conditions and the risk that SAGE may not be able to satisfy the customary closing conditions related to the proposed offering; the potential that future pre-clinical and clinical results may not support further development of SAGE’s product candidates or that SAGE may not be able to successfully demonstrate the efficacy and safety of its product candidates at each stage of development in manner sufficient to obtain approval; actions or decisions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; the potential for unexpected adverse events in the conduct of one of SAGE’s clinical trials to impact its ability to continue the clinical trial or further development of a product candidate; the risk that SAGE may encounter other unexpected hurdles or issues in the development and manufacture of its product candidates that may impact its timing or progress, as well as those risks more fully discussed in the section entitled "Risk Factors" in SAGE's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in SAGE's subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent SAGE's views only as of today and should not be relied upon as representing its views as of any subsequent date. SAGE explicitly disclaims any obligation to update any forward-looking statements.
Investor Contact: Paul Cox, Sage Therapeutics paul.cox@sagerx.com 617-299-8377 Media Contact: Dan Budwick, Pure Communications dan@purecommunicationsinc.com 973-271-6085
